Wednesday, April 22, 2026
33.4 C
Bengaluru

Specially Designed Case Study based Modules for Pharma Marketing Professionals

DEPA 2.0 Workshop – Open to participants from all companies – Starting February 5th, 2022.

We can also conduct a customized workshop to address your company’s specific needs on dates and timelines convenient to you.

The 4- Module Workshop series will be moderated by Anup Soans with international and Indian faculty – Dr. Peter Velev, a medical doctor and pharma industry veteran, and Salil Kallianpur, pharma marketing veteran and digital brand coach.

Objective: More than digitalizing your product promotions, the case calls for building and engaging your brand community through digital solutions that create memorable customer experiences.

With the new normal emerging, the traditional Pharma commercial model needs to be relooked by exploring alternative channels of engagement, which offer opportunities to create value for customers.

Company-specific digital adoption workshops to experience how a brand can be promoted using the omnichannel approach with field force involvement.

Interactive Webinars extended with Virtual Event – 4 Modules – 2.0 hours each over 4 weeks.

Register Now – https://medicinman.net/depa20-request-payment-link/register-for-depa-2-0/

https://medicinman.net/depa20-request-payment-link/register-for-depa-2-0/

Hot this week

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Topics

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img